SG&A Expense (Quarterly) Chart

View SG&A Expense (Quarterly) for ONC.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View SG&A Expense (Quarterly) Chart
Start Trial

Historical SG&A Expense (Quarterly) Data

View and export this data back to 2015. Start Trial.
Date Value
March 31, 2026 556.75M
December 31, 2025 557.71M
September 30, 2025 529.71M
June 30, 2025 539.80M
March 31, 2025 459.29M
December 31, 2024 502.87M
September 30, 2024 455.22M
June 30, 2024 443.73M
March 31, 2024 427.43M
December 31, 2023 416.55M
September 30, 2023 364.42M
June 30, 2023 395.03M
March 31, 2023 328.50M
December 31, 2022 328.98M
September 30, 2022 322.89M
June 30, 2022 331.40M
March 31, 2022 294.57M
December 31, 2021 306.50M
September 30, 2021 269.23M
June 30, 2021 232.29M
March 31, 2021 182.11M
December 31, 2020 208.21M
Date Value
September 30, 2020 160.84M
June 30, 2020 124.05M
March 31, 2020 107.08M
December 31, 2019 143.35M
September 30, 2019 105.00M
June 30, 2019 82.25M
March 31, 2019 57.64M
December 31, 2018 72.49M
September 30, 2018 48.82M
June 30, 2018 45.16M
March 31, 2018 28.92M
December 31, 2017 27.42M
September 30, 2017 15.64M
June 30, 2017 10.78M
March 31, 2017 8.769M
December 31, 2016 8.337M
September 30, 2016 4.722M
June 30, 2016 3.904M
March 31, 2016 3.134M
December 31, 2015 2.95M
September 30, 2015 4.361M

SG&A Expense (Quarterly) Range, Past 5 Years

View SG&A Expense (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

SG&A Expense (Quarterly) Benchmarks

View SG&A Expense (Quarterly) Benchmarks
Start Trial
CRISPR Therapeutics AG 17.18M
AC Immune SA 5.326M
Idorsia Ltd. 77.58M
ADC Therapeutics SA 22.60M
MoonLake Immunotherapeutics 15.51M